NEW YORK (GenomeWeb News) – OriGene Technologies today announced the completion of its $21.3 million Series C financing round.

Qiming Venture Partners and Kleiner Perkins Caufield Byers China led the round, while existing investor IDG-Accel also participated, OriGene said.

The company intends to use the financing to "advance our growth strategy and operations," Wei-Wu He, OriGene's chairman and CEO, said in a statement, without elaborating.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A Scientific Reports editor resigns over a new policy at the journal allowing researchers to pay to fast track the peer review of their manuscripts, and poll.

The National Cancer Institute's Harold Varmus discusses the state of cancer research with the New York Times.

In PNAS this week: rare variants linked to bleeding disorder, comparison of whole-exome and whole-genome sequencing, and more.

George Church tells The Sunday Times that his group has inserted some woolly mammoth genes into elephant cells.